Clinical Trials Directory

Trials / Completed

CompletedNCT07123259

Ulcer Pomegranate Muffins

Anti-Ulcerative Colitis Activity of Pomegranate (Punica Granatum L.) Peel Powder Muffins in Patients With Gastric Ulcer

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
82 (actual)
Sponsor
University of Lahore · Academic / Other
Sex
All
Age
40 Years – 60 Years
Healthy volunteers
Accepted

Summary

Pomegranate (Punica granatum L.) peel powder, known for its potent antioxidant, anti-inflammatory, and antimicrobial properties, has shown promise in the dietary management of gastrointestinal disorders. In recent clinical observations, incorporating pomegranate peel powder into muffins consumed by patients with gastric ulcers demonstrated potential anti-ulcerative colitis activity. The bioactive compounds in the peel, such as polyphenols (punicalagins, ellagic acid), help reduce oxidative stress and modulate inflammatory pathways in the gut. Patients consuming these enriched muffins reported improvements in gastrointestinal symptoms, reduced mucosal inflammation, and enhanced mucosal healing, suggesting a supportive role of pomegranate peel as a functional food ingredient in managing gastric and colitis-related conditions.

Detailed description

2\. Materials and Methods 2.1. Ethical Statement The study received ethical approval from the Research Ethics Committee (REC) of the University of Lahore (REC-UOL-/530/08/24). Informed consent was obtained from all participants, who were fully informed about the study's aims, methods, risks, and benefits, and were given the opportunity to ask questions and withdraw at any time. 2.2. Settings The research was undertaken at Umair Clinic, Gondal Chowk, Kacha Jail Road, Lahore, whereas laboratory work and muffin preparation were done at the Food Science and Nutrition Laboratory (FASH Lab 502), UIDNS, The University of Lahore, Lahore, Pakistan. 2.3. Subjects A randomized controlled trial (RCT) was conducted using a purposive sampling strategy. Initially, 88 patients were enrolled, accounting for a projected 20% dropout rate. One patient was excluded for not meeting the inclusion criteria, resulting in 87 eligible participants. These were randomly and equally assigned into three groups, with 29 patients in each group. During the study, two patients were excluded from the placebo Group (T0), leaving 27 participants. In Group 2 (T1), two patients were excluded, and one participant voluntarily withdrew due to personal health issues from Group 3 (T2). Ultimately, a total of 82 patients completed the 8-week trial study. 2.4. Intervention groups Group T1 received one muffin per day enriched with 1.5 g of pomegranate peel powder (PPP), alongside conventional medical therapy. Group T2 received two PPP-enriched muffins per day (totaling 3 g of PPP), in addition to conventional therapy. The placebo group received one whole wheat muffin per day without PPP supplementation. All participants consumed their assigned muffins once daily for 8 weeks 2.4.1 Demographic Profile Demographic data among ulcer patients, including age, gender, and socioeconomic status, were collected at baseline using a structured questionnaire (Saber et al., 2021).

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTWHOLE WHEAT MUFFIN400g whole wheat flour was used for the development of muffins
COMBINATION_PRODUCT1.5g enriched pomegranate muffins1.5 g of pomegranate peel powder (PPP), alongside conventional medical therapy
COMBINATION_PRODUCT3g enriched pomegranate muffins3 g of pomegranate peel powder (PPP), alongside conventional medical therapy

Timeline

Start date
2024-08-10
Primary completion
2024-10-10
Completion
2024-10-12
First posted
2025-08-14
Last updated
2025-08-19

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT07123259. Inclusion in this directory is not an endorsement.